Danica Pension Livsforsikringsaktieselskab, a Danish pension fund, established a new position in Alignment Healthcare, Inc. (NASDAQ:ALHC) during the fourth quarter by purchasing 2 million shares valued at roughly $39.5 million, according to HoldingsChannel.com. The investment reflects broader institutional appetite for the healthcare company, which specializes in value-based care for Medicare Advantage beneficiaries.
Multiple other major institutional investors have simultaneously expanded their stakes in Alignment Healthcare. Vanguard Group Inc. increased its holdings by 10.9% in the fourth quarter, now owning 15.5 million shares valued at $305.98 million. Wellington Management Group LLP lifted its position by 167.3% in the third quarter to 11.1 million shares worth $193.5 million. Assenagon Asset Management S.A. dramatically boosted its holdings by 6,708% in the fourth quarter, acquiring 1.8 million additional shares to reach a total position valued at $35.1 million. Invesco Ltd. increased its stake by 122.3% in the second quarter, now holding 4.2 million shares valued at $58.4 million.
Institutional investors and hedge funds collectively own 86.19% of Alignment Healthcare's outstanding stock. Insiders hold 7% of the company. Stock price movement reflects recent momentum, with shares trading at $22.54 on Friday and ranging between a 52-week low of $11.63 and high of $23.87. The company has a market capitalization of $4.66 billion.
Recent insider transactions show mixed signals about company direction. President Dawn Christine Maroney sold 36,749 shares on March 18th at an average price of $17.84, reducing her position by 3.35%. CEO John E. Kao sold 250,000 shares on April 7th at an average price of $21.01, representing a 10.62% decrease in his stake. The CEO's sale was executed under a pre-arranged trading plan. Over the past 90 days, insiders sold 1.47 million shares worth $28.7 million.
Alignment Healthcare beat first-quarter earnings expectations, reporting earnings per share of $0.05 against a consensus estimate of $0.02 and revenue of $1.24 billion versus $1.22 billion expected. Management updated second-quarter revenue guidance to approximately $1.3 billion and full-year 2026 revenue guidance to approximately $5.2 billion, both roughly aligned with consensus expectations. However, the company reported a slightly negative net margin of negative 0.02% in the quarter.
Wall Street analysts hold mixed views on the stock's near-term prospects. Zacks upgraded Alignment Healthcare from "hold" to "strong-buy" rating following the earnings beat. KeyCorp maintained an "overweight" rating with a $28.00 target price, while Wolfe Research initiated coverage with an "outperform" rating and $24.00 price target. UBS raised its target price from $18.00 to $21.00 with a "neutral" rating. Wall Street Zen downgraded the stock from "buy" to "hold" on March 7th. According to MarketBeat.com, the company has an average analyst rating of "Moderate Buy" with a consensus price target of $24.67.
